NEUROMETRIX INC (NURO)
US6412558800 - Common Stock
Overall NURO gets a fundamental rating of 3 out of 10. We evaluated NURO against 192 industry peers in the Health Care Equipment & Supplies industry. While NURO has a great health rating, there are worries on its profitability. NURO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
NURO had negative earnings in the past year.
In the past year NURO has reported a negative cash flow from operations.
NURO had negative earnings in each of the past 5 years.
NURO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -30.48%, NURO perfoms like the industry average, outperforming 45.31% of the companies in the same industry.
Looking at the Return On Equity, with a value of -32.50%, NURO is in line with its industry, outperforming 55.21% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.48% | ||
| ROE | -32.5% | ||
| ROIC | N/A |
ROA(3y)-19.18%
ROA(5y)-27.69%
ROE(3y)-20.41%
ROE(5y)-50.01%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NURO has a Gross Margin of 66.94%. This is in the better half of the industry: NURO outperforms 73.44% of its industry peers.
NURO's Gross Margin has improved in the last couple of years.
NURO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.94% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.03%
GM growth 5Y7.84%
2. Health
2.1 Basic Checks
NURO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NURO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for NURO has been increased compared to 5 years ago.
NURO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -9.54, we must say that NURO is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.54, NURO is doing worse than 79.17% of the companies in the same industry.
NURO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.54 |
ROIC/WACCN/A
WACC10.02%
2.3 Liquidity
A Current Ratio of 16.81 indicates that NURO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 16.81, NURO belongs to the top of the industry, outperforming 98.44% of the companies in the same industry.
NURO has a Quick Ratio of 15.55. This indicates that NURO is financially healthy and has no problem in meeting its short term obligations.
NURO has a better Quick ratio (15.55) than 98.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.81 | ||
| Quick Ratio | 15.55 |
3. Growth
3.1 Past
The earnings per share for NURO have decreased strongly by -221.94% in the last year.
Looking at the last year, NURO shows a very negative growth in Revenue. The Revenue has decreased by -28.60% in the last year.
NURO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.18% yearly.
EPS 1Y (TTM)-221.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1486.93%
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-7.18%
Revenue growth 5Y-18.18%
Revenue growth Q2Q-28.77%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NURO. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
NURO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEUROMETRIX INC
NASDAQ:NURO (5/1/2024, 5:17:04 PM)
4.44
+0.07 (+1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.84M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -30.48% | ||
| ROE | -32.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 66.94% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 16.81 | ||
| Quick Ratio | 15.55 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-221.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-28.6%
Revenue growth 3Y-7.18%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y